Fiche publication
Date publication
juin 2023
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain
,
Pr GHIRINGHELLI François
,
Dr ROYER Bernard
,
Pr SCHMITT Antonin
Tous les auteurs :
Schmitt A, Royer B, Boidot R, Berthier J, Ghiringhelli F
Lien Pubmed
Résumé
Esophageal cancer is a cancer with poor prognosis and the standard 1 line treatment for metastatic or recurrent EC is systemic chemotherapy with doublet chemotherapy based on platinum and 5-fluorouracil (5-FU). However, 5-FU could be a source of severe treatment-related toxicities due to deficiency of dihydropyrimidine dehydrogenase (DPD). In this case report, a 74-year-old man with metastatic esophageal cancer was found to have partial DPD deficiency based on uracilemia measurements (about 90 ng/mL). Despite this, 5-FU was safely administered thanks to therapeutic drug monitoring (TDM). The case report highlights the importance of TDM in administering 5-FU to patients with partial DPD deficiency, as it allows individualized dosing and prevents severe toxicity.
Mots clés
5-Fu (5-Fluorouracil), DPD deficiency, esophageal cancer, therapeutic drug monitoring, uracilemia
Référence
Front Oncol. 2023 06 20;13:1187052
